Phase 1 trial shows treprostinil skin patch’s potential

Transdermal delivery could be alternative to existing treprostinil administration methods, study results suggest.

United Therapeutics Acquires Thymmune Therapeutics

United Therapeutics acquired Thymmune Therapeutics, which is developing regenerative cell therapies for potential post-transplant treatment.

Medicare, some insurers to cover OxiWear oxygen monitor

Eligible patients can now access OxiWear through Medicare and participating insurance providers. The device continuously monitors blood oxygen.

FDA approves UT’s device to assess donor lungs

The FDA gave pre-market approval to United Therapeutic’s LungFX device to assess donor lungs outside the body.

Ralinepag shows delayed disease progression in PAH study

Ralinepag met a primary goal to delay disease progression in a Phase 3 stud. The study also met several important secondary goals.

Gossamer announces topline results from Phase 3 seralutinib study

Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24.

Pulmovant completes Phase 2 study enrollment for PH-ILD drug

Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD.

Cereno to expand drug development focus to PH-ILD

Cereno Scientific plans to focus development of its HDAC inhibitor CS014 on PH related to interstitial lung disease.